. Respiratory movements and flow at the airway opening were monitored us-FIGURE 1. The rebreathing circuit and monitors used to determine serial BHTs.
ing chest and abdomen surface monitors (DENSA pneumograph DMS-100, DENSA Ltd, United Kingdom) and a pneumotachograph (Fleisch, Erich Jaeger, Germany), respectively. These were documented on a multichannel recorder (Model No RS 3600, Gould Medical Ltd, Coventry, United Kingdom). The EtCO2 was recorded with a capnograph (Multicap CNO-103, Datex Instrumentation Corp, Finland). After priming the system with 100% oxygen and calibrating the capnograph, surface apnea monitors, and the pneumotachograph, the patients were connected to the circuit with the nose clip in place. The procedure was explained, and the patients were allowed a settling period of 30 s. The Et-CO2 recorded at this instant was termed as the basal EtCO2. A change in the EtCO2 of 1% corresponded to 7.6 mm Hg starting from a pretest level of 0%=(.0 mm of Hg. The basal breathholding maneuver was then performed by giving all patients the identical instruction: "Hold your breath at the end of a normal breath and keep holding it for as long as you can." At the end of the breath-holding maneuver, the patients remained connected to the circuit and continued to rebreathe. The breath-holding maneuvers were repeated at each 1% increase in EtCO2 up to the maximal tolerated level or 10% if this was achieved. Tolerance was defined as the maximal discomfort in the form of suffocation, bursting headache, or lightheadedness experienced by the patient and necessitating disconnection from the rebreathing circuit. The EtCO2 concentration prior to termination of the test was considered the "maximal EtCO2-and the corresponding BHT was recorded as the "maximal BHT." One trial run was discarded, and the second set of readings was considered. The BHT was calculated as the period of zero flow recorded on the moving paper recorder. Throughout the test, the inspired oxygen in the breathing circuit was kept greater than 60% to avoid hypoxia. Breath holding with swallowing interference as well as breath holding in which chest and abdominal movements were recorded throughout were discarded.
Each subject had at least three values of BHT at successive Et-CO2 concentrations which were plotted, and the individual slope of BHT/EtCO2 was derived for each patient.
Statistical Analysis
The values are expressed as mean ± SD. Intergroup comparisons of basal and maximal EtCO2 and BHT and the slope of their relationship were carried out using simple factorial analysis of variance with post hoc comparison by Tukey's Highest Significant Difference test. Univariate regression analysis was used to determine the correlation between slope of BHT/EtCO2 and body mass index (BMI) and age. Statistical significance was considered at a probability of less than 0.05. The analysis was carried out with a statistical software program SPSS version 5 (Statistical Package for Social Sciences, SPSS, Chicago, IL).
RESULTS
In our group of 76 subjects, 30 had OSAS (mean apnea index, 46.3+8.3) and 16 were nonapneic snorers. Their mean age, sex distribution, and BMI are described in Table 1 . All patients had normal lung function tests and normal daytime blood gases at the time of the study. The subgroups, therefore, differed only in terms of their BMI and apnea index.
As shown in Table 2 , OSAS patients had a significantly higher basal EtCO2 compared with that of normal subjects and snorers. The basal BHT (seconds) was significantly shorter in OSAS compared with normal subjects and snorers. The maximal EtCO2 that OSAS subjects could tolerate was significantly higher than in normal subjects but marginally higher than in snorers (p=0.052). The maximal BHT in OSAS subjects was significantly lower than in normal subjects. It was also lower in OSAS subjects as compared with snorers, but the difference did not achieve statistical significance. The proportion of subjects who tolerated an EtCO2 of more than 8% was significantly greater in OSAS subjects (20 of 30) compared with snorers (8 of 16) and normal subjects (9 in OSAS patients (2,834 ± 829.5 mL) and snorers (2,920 ± 586.5 mL) were comparable (p=0.792).
DISCUSSION
This study shows that OSAS patients have a different relationship between BHT and EtCO2 as compared with normal subjects and snorers. The basal BHT is shorter with a higher basal EtCO2, and the slope BHT/EtCO2 is steeper. The steeper slope could be caused by a curvilinear relationship between BHT/EtCO2 combined with a shift to the right due to the higher basal EtCO2. Respiratory drive may be related to BMI. A previous study showed that BHT was shorter in obese subjects compared with normal subjects, though this was not specifically associated with EtCO2.9 Miyamura et all' studied the slope of the hypercapnic ventilatory response and found it to be lower in subjects with a high BMI compared with that of the normal subjects. However, in this study, differences in BHT seen in sleep apnea could not be attributed to obesity or to an abnormality of FRC.
The determinants of a maximal voluntary breath hold are initial lung volume, prior oxygenation, and prior PaCO2.2'11 By flushing our rebreathing circuit with 100% oxygen prior to the test, we ensured that hypoxemia or variation in rates of fall of oxygen saturation did not affect the BHT. During the test, the subject's psychological willpower and endurance influence the duration of the breath holding. The breakpoint of breath holding is preceded by the onset of respiratory movements. These irregular contractions of the inspiratory muscles reduce the unpleasant sensation in the lower thorax and abdomen that occurs progressively through a breath-holding period.'2 Campbell et al'3 showed that complete muscle paralysis with curare caused prolongation of the BHT in the absence of the unpleasant sensation of breath holding and concluded that inspiratory muscle activity was the final common pathway determining the breakpoint. The onset of electrical activity during a breath holding period is closely re- (Table 2 ). In addition, OSAS patients tolerated breath holding at a higher maximal EtCO2. This may indicate a greater tolerance of inspiratory loading inevitably seen with this experimental setup, perhaps suggesting diminished ventilatory response to CO2.
Another possibility for the shorter BHTs in OSAS and the absence of any difference between snorers and normal subjects can be derived from the continuum hypothesis of sleep-disordered breathing.1516 Accordingly, normal subjects, snorers-which would include a diverse group of symptomatic individuals with and without an increased upper airway resistance (not assessed in the present study), and OSAS patients have a progressive increase in the severity of symptoms associated with a reduction of BHT. All OSAS patients were already established on nasal CPAP. A previous study on the effect of nasal CPAP on daytime hypercapnic ventilatory response17
showed that the slope of the ventilatory response remains essentially unchanged in the absence of daytime hypercapnia. One mechanism for the depressed ventilatory response to CO2 in OSAS could be sleep fragmentation, since a night of total sleep deprivation produces a reversible decrease in the hypercapnic ventilatory response in normal human volunteers. '8 However, in the present study, patients were not sleep-deprived, being already maintained on nasal CPAP and corroborated by their arousal index. A further study would be needed to establish whether breath holding is changed by institution of CPAP therapy.
Recent evidence has suggested that increased ventilatory effort may be the stimulus to arousal from sleep.19 The different threshold for perception of breathing discomfort from the respiratory muscles may explain the variability in the length of apneas prior to arousal in different patients. A further study of the breath-holding response is needed within a large group of patients with OSAS to investigate whether there is any link between the tolerance of respiratory discomfort during a breath-holding maneuver and the length of time to arousal during apnea in patients with OSAS.
